trending Market Intelligence /marketintelligence/en/news-insights/trending/cZ-jnNkRwzT-94j8O_W6rg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Horizon Pharma closes $326.8M ordinary share offering to repay debt

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Horizon Pharma closes $326.8M ordinary share offering to repay debt

Horizon Pharma PLC closed a public offering of 14,081,632 ordinary shares priced at $24.50 each.

Shares sold include the additional 1,836,734 stocks the offering's underwriters could have bought as part of their overallotment option.

Net proceeds from the offering are about $326.8 million. The company previously said it plans to use net proceeds, along with cash on hand, to repay about $550 million of its outstanding debt.

The debt includes a portion of the loans under Horizon Pharma's credit agreement and a portion of an amount of its 6.625% senior notes due 2023.

Citigroup, Morgan Stanley, Goldman Sachs & Co. LLC and Cowen acted as joint book-running managers for the offer.

Dublin-based Horizon Pharma develops medicines that address rare and rheumatic diseases.